Journals / Turkish Journal of Hematology / 2016 / Cilt: 33 - Sayı: 4

Erişkin Burkitt Hücreli Löseminin Klinik Pratikteki Seyri

The Prognosis of Adult Burkitt's Cell Leukemia in Real-Life

Pages
281–285
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our results are in agreement with a few prospective noncomparative studies suggesting no further need for stem cell transplantation in BCL.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Many studies reported an improved prognosis in patients with Burkitt's lymphoma obviating the need of stem cell transplantation.
📊
Key Findings & Data:Materials and Methods: In this retrospective analysis, BCL patients aged between 16 and 63 who were admitted between 2000 and 2014 to the hospitals of Hacettepe or Gazi University and were treated with intensive therapies aimed at cure were included.
💡
Conclusion & Impact:Our results are in agreement with a few prospective noncomparative studies suggesting no further need for stem cell transplantation in BCL.
🔬Design:Research Article
📍Scope:2000 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Many studies reported an improved prognosis in patients with Burkitt's lymphoma obviating the need of stem cell transplantation. However, prognosis of the advanced disease [i.e. Burkitt's cell leukemia (BCL)] has not been reported with current treatment modalities except for a few prospective trials. The aim of this study is to compare the prognoses of BCL patients with similarly treated and nontransplanted patients with other types of acute lymphoblastic leukemia (ALL) and with ALL patients that underwent allogeneic stem cell transplantation (ASCT) in their first remissions. Materials and Methods: In this retrospective analysis, BCL patients aged between 16 and 63 who were admitted between 2000 and 2014 to the hospitals of Hacettepe or Gazi University and were treated with intensive therapies aimed at cure were included. All ALL patients who were treated with a similar protocol not including transplantation during the same period (NT-ALL group) and all ALL patients who underwent ASCT in the first complete remission during the same period (T-ALL group) served as control groups. Results: The central nervous system or extramedullary involvement rates, lactate dehydrogenase levels, and white blood cell counts at diagnosis were higher in the BCL group than the NT-ALL group and these differences were significant. BCL patients had disease-free survival (DFS) durations comparable with the T-ALL cohort but NTALL patients had significantly shorter DFS durations. Both cumulative relapse incidence and cumulative nonrelapse mortality were higher in NT-ALL patients compared to the T-ALL group and BCL patients. Conclusion: DFS in BCL patients treated with a widely accepted modern regimen, R-HyperCVAD, is comparable to results in other ALL patients receiving allogeneic transplantation. Our results are in agreement with a few prospective noncomparative studies suggesting no further need for stem cell transplantation in BCL.

Özet

Amaç: Yapılan birçok çalışmada Burkitt lenfomanın seyrinin düzeldiği, hatta kemik iliği nakli ihtiyacının ortadan kalktığı ileri sürülmektedir. Ancak birkaç ileriye dönük çalışma haricinde, güncel tedavi yöntemleri altında hastalığın lösemik formunun seyri hakkında araştırma yapılmamıştır. Bu çalışmanın amacı Burkitt hücreli lösemi (BHL) hastalarının klinik seyrinin, benzer tedavi alan ve transplantasyon uygulanmayan diğer akut lenfoblastik lösemi (ALL) hastaları ve ilk remisyonlarında allojenik kök hücre nakli (AKHN) uygulanan ALL hastalarıyla kıyaslanmasıdır.Gereç ve Yöntemler: Geriye dönük olarak tasarlanan bu çalışmaya yaşları 16 ile 63 arasında değişen, 2000 ile 2014 yılları arasında Hacettepe ve Gazi Üniversitesi Hastaneleri'ne başvurup kür amacıyla intensif tedavi verilen BHL hastaları alınmıştır. Transplantasyon haricinde benzer tedavi protokolüyle tedavi edilen tüm ALL hastaları (NT-ALL) ve aynı dönemde ilk tam remisyonlarında AKHN uygulanan hastalar (T-ALL) kontrol grupları olarak çalışmaya alınmışlardır. Bulgular: Santral sinir sistemi ya da ekstra medüller tutulum hızları, tanı anındaki laktat dehidrogenaz düzeyleri ve beyaz küre sayısı BHL hastalarında NT-ALL hastalarına göre istatistiksel olarak anlamlı olacak şekilde daha yüksekti. BHL hastaları T-ALL hastalarıyla benzer hastalıksız sağkalım (HS) süresine sahip olmakla beraber, NTALL hastalarında HS süresi önemli oranda azalmıştı. Kümülatif nüks insidansı ve kümülatif nüks dışı ölümler NT-ALL hastalarında T-ALL ve BHL hastalarında kıyasla daha fazlaydı.Sonuç: Sonuç olarak, geniş kabul gören modern bir rejim olan R-HyperCVAD ile tedavi edilen BHL hastalarında HS süresi allojenik transplantasyon uygulanmış diğer ALL hastaları ile benzer bulundu. Bizim çalışmamızın sonuçları, literatürde ileri dönük dizayn edilmiş ancak kontrol grupları ile karşılaştırma olmadan yapılmış ve BHL'de transplantasyon gerekmediğini öne süren az sayıdaki çalışma ile örtüşmektedir.

🔖

Cite This Article

MALKAN, Ü. Y., GÜNEŞ, G., GÖKER, H., HAZNEDAROĞLU, İ. C., ACAR, K., ELİAÇIK, E., ETGÜL, S., ASLAN, T., BALABAN, S., DEMİROĞLU, H., ÖZCEBE, O. İ., SAYINALP, N., AKSU, S., BÜYÜKAŞIK, Y. (2016). Erişkin Burkitt Hücreli Löseminin Klinik Pratikteki Seyri. Turkish Journal of Hematology, Cilt: 33 - Sayı: 4, 281–285. https://ajindex.com/articles/412787

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt's and Burkitt's-type lymphoma or acute lymphoblastic leukemia. Cancer 2006;106:1569-1580. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-1154.
  2. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 2007;40:381-387. Team RDC. R: A Language and Environment for Statistical Computing. Vienna, Austria, R Foundation for Statistical Computing, 2012.
  3. Hoelzer D, Walewski J, Döhner H, Schmid M, Hiddemann W, Baumann A, Serve H, Dührsen U, Hüttmann A, Thiel E, Dengler J, Kneba M, Schuler M, Schmidt-Wolf I, Beck J, Hertenstein B, Reichle A, Domanska-Czyz K, Fietkau R, Horst HA, Rieder H, Schwartz S, Burmeister T, Goekbuget N. Substantially improved outcome of adult Burkitt's non-Hodgkin lymphoma and leukemia patients with rituximab and a short-intensive chemotherapy; report of a large prospective multicenter trial. Blood 2012;120:667a (abstract). Intermesoli T, Rambaldi A, Rossi G, Delaini F, Romani C, Pogliani EM, Pagani C, Angelucci E, Terruzzi E, Levis A, Cassibba V, Mattei D, Gianfaldoni G, Scattolin AM, Di Bona E, Oldani E, Parolini M, Gökbuget N, Bassan R. High cure rates in Burkitt's lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. Haematologica 2013;98:1718-1725.
  4. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992- 2001. Blood 2006;107:265-276.
  5. Magrath I, Adde M, Shad A, Venzon D, Seibel N, Gootenberg J, Neely J, Arndt C, Nieder M, Jaffe E, Wittes RA, Horak ID. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996;14:925-934.
  6. Castillo JJ, Winer ES, Olszewski AJ. Population-based prognostic factors for survival in patients with Burkitt's lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database. Cancer 2013;119:3672-3679.
  7. Costa LJ, Xavier AC, Wahlquist AE, Hill EG. Trends in survival of patients with Burkitt's lymphoma/leukemia in the USA: an analysis of 3691 cases. Blood 2